Systemic inflammation and prognosis in patients with RAS / BRAF wild‐type metastatic colorectal cancer receiving anti‐EGFR therapy: A real‐world cohort study
Abstract Aim Colorectal cancer outcomes are heterogeneous, so greater prognostic discrimination is needed. In this retrospective real‐world analysis, we assessed the prognostic effect of markers of systemic inflammation in a cohort of patients with RAS/BRAF wild‐type metastatic colorectal cancer (mCRC) who received ant...